OrbiMed’s Big Fund Signals A Potential Return To Health For VCs
This article was originally published in The Pink Sheet Daily
The largest dedicated health care investor has closed a huge new fund, which came almost entirely from existing investors. OrbiMed isn’t the only firm capitalizing on the robust biotech IPO market. A few VCs are starting to take gains from IPO winners through secondary offerings.